Lyell Immunopharma Ownership 2024 | Who Owns Lyell Immunopharma Now?
Institutional Ownership
52.44%
Insider Ownership
15.34%
Retail Ownership
32.23%
Institutional Holders
116.00
Lyell Immunopharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MWG MANAGEMENT LTD. | 7.93% | 31.93% | 20,162,332 | - | - | 29,235,381 | Jun 30, 2024 |
| ORLAND PROPERTIES LTD | 5.94% | 16.63% | 15,093,969 | - | - | 21,886,255 | Jun 30, 2024 |
| BLACKROCK INC. | 5.31% | 0.00% | 13,495,132 | -397,495 | -2.86% | 19,567,942 | Jun 30, 2024 |
| VANGUARD GROUP INC | 5.27% | 0.00% | 13,398,298 | 9,873 | 0.07% | 19,427,532 | Jun 30, 2024 |
| FORESITE CAPITAL MANAGEMENT IV, LLC | 3.27% | 8.11% | 8,325,000 | - | - | 12,071,250 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.10% | 0.00% | 7,872,369 | 1,140,892 | 16.95% | 11,416,000 | Jun 30, 2024 |
| WUXI APPTEC CO., LTD. | 3.02% | 47.74% | 7,682,156 | -498,522 | -6.09% | 11,139,126 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 2.52% | 0.18% | 6,405,098 | 6,205,598 | 3110.58% | 9,287,392 | Jun 30, 2024 |
| ALPHABET INC. | 2.31% | 0.43% | 5,865,125 | - | - | 8,504,431 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.58% | 0.00% | 4,012,053 | -4,968 | -0.12% | 5,818,669 | Jun 30, 2024 |
| STATE STREET CORP | 1.50% | 0.00% | 3,818,320 | 100,357 | 2.70% | 5,536,564,000 | Jun 30, 2024 |
| SC CHINA HOLDING LTD | 1.20% | 0.18% | 3,045,997 | - | - | 4,995,435 | Jun 30, 2024 |
| FMR LLC | 1.08% | 0.00% | 2,733,462 | -35,800 | -1.29% | 3,963,520 | Jun 30, 2024 |
| MIC CAPITAL MANAGEMENT UK LLP | 0.68% | 0.55% | 1,740,569 | - | - | 2,523,825 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 0.66% | 0.55% | 1,670,000 | -1,685,000 | -50.22% | 2,421,500 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.55% | 0.00% | 1,389,041 | -52,929 | -3.67% | 2,014,109,000 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.51% | 0.00% | 1,297,642 | 18,230 | 1.42% | 1,881,581 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.40% | 0.00% | 1,004,642 | 40,800 | 4.23% | 1,456,731 | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 0.39% | 0.00% | 985,336 | 748,582 | 316.19% | 1,428,737 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.33% | 0.00% | 843,257 | -8,798 | -1.03% | 1,222,722 | Jun 30, 2024 |
Lyell Immunopharma's largest institutional shareholder is MWG MANAGEMENT LTD., holding 7.93% of the company's total share outstanding, currently valued at $29.24M. The top 10 institutional shareholders own together 40.24% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| WUXI APPTEC CO., LTD. | 3.02% | 47.74% | 7,682,156 | -498,522 | -6.09% | 11,139,126 | Jun 30, 2024 |
| MWG MANAGEMENT LTD. | 7.93% | 31.93% | 20,162,332 | - | - | 29,235,381 | Jun 30, 2024 |
| ORLAND PROPERTIES LTD | 5.94% | 16.63% | 15,093,969 | - | - | 21,886,255 | Jun 30, 2024 |
| FORESITE CAPITAL MANAGEMENT IV, LLC | 3.27% | 8.11% | 8,325,000 | - | - | 12,071,250 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 0.66% | 0.55% | 1,670,000 | -1,685,000 | -50.22% | 2,421,500 | Jun 30, 2024 |
| MIC CAPITAL MANAGEMENT UK LLP | 0.68% | 0.55% | 1,740,569 | - | - | 2,523,825 | Jun 30, 2024 |
| ALPHABET INC. | 2.31% | 0.43% | 5,865,125 | - | - | 8,504,431 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 2.52% | 0.18% | 6,405,098 | 6,205,598 | 3110.58% | 9,287,392 | Jun 30, 2024 |
| SC CHINA HOLDING LTD | 1.20% | 0.18% | 3,045,997 | - | - | 4,995,435 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.21% | 0.13% | 526,066 | 526,066 | 100.00% | 762,796 | Jun 30, 2024 |
| CLARIUS GROUP, LLC | 0.16% | 0.04% | 399,168 | - | - | 578,794 | Jun 30, 2024 |
| VIRTUS ETF ADVISERS LLC | 0.01% | 0.02% | 34,952 | -7,940 | -18.51% | 50,680 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.04% | 0.02% | 96,288 | -838 | -0.86% | 139,618 | Jun 30, 2024 |
| BBR PARTNERS, LLC | 0.06% | 0.02% | 164,041 | - | - | 237,859 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.03% | 0.01% | 70,174 | -40,545 | -36.62% | 101,752 | Jun 30, 2024 |
| CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 0.01% | 0.01% | 29,951 | -18,904 | -38.69% | 43,429 | Jun 30, 2024 |
| AIGEN INVESTMENT MANAGEMENT, LP | 0.01% | 0.01% | 17,908 | 17,908 | 100.00% | 25,967 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.06% | 0.00% | 139,880 | 139,880 | 100.00% | 202,826 | Jun 30, 2024 |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 0.05% | 0.00% | 128,203 | 42,452 | 49.51% | 185,894 | Jun 30, 2024 |
| FORTIS CAPITAL MANAGEMENT LLC | 0.00% | 0.00% | 12,092 | - | - | 17,534 | Jun 30, 2024 |
The largest Lyell Immunopharma shareholder by % of total assets is WUXI APPTEC CO., LTD.. The company owns 7.68M shares of Lyell Immunopharma (LYEL), representing 47.74% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2.52% | 0.18% | 6,405,098 | 6,205,598 | 3110.58% | 9,287,392 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.10% | 0.00% | 7,872,369 | 1,140,892 | 16.95% | 11,416,000 | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 0.39% | 0.00% | 985,336 | 748,582 | 316.19% | 1,428,737 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.21% | 0.13% | 526,066 | 526,066 | 100.00% | 762,796 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.14% | 0.00% | 367,677 | 367,677 | 100.00% | 533,132 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.12% | 0.00% | 312,406 | 312,406 | 100.00% | 452,989 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 0.08% | 0.00% | 192,609 | 159,609 | 483.66% | 279,283 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.06% | 0.00% | 139,880 | 139,880 | 100.00% | 202,826 | Jun 30, 2024 |
| STATE STREET CORP | 1.50% | 0.00% | 3,818,320 | 100,357 | 2.70% | 5,536,564,000 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.03% | 0.00% | 86,454 | 86,454 | 100.00% | 125,358 | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.22% | 0.00% | 553,163 | 69,712 | 14.42% | 802,086 | Jun 30, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.06% | 0.00% | 144,957 | 49,000 | 51.06% | 210,188 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 0.09% | 0.00% | 220,790 | 45,960 | 26.29% | 320,146 | Jun 30, 2024 |
| AMERICAN CENTURY COMPANIES INC | 0.11% | 0.00% | 279,425 | 42,752 | 18.06% | 405,166 | Jun 30, 2024 |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 0.05% | 0.00% | 128,203 | 42,452 | 49.51% | 185,894 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.40% | 0.00% | 1,004,642 | 40,800 | 4.23% | 1,456,731 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.26% | 0.00% | 671,966 | 38,487 | 6.08% | 974,350 | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | 0.05% | 0.00% | 124,320 | 38,328 | 44.57% | 180,264 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.16% | 0.00% | 400,853 | 27,247 | 7.29% | 581,237 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.02% | - | 40,098 | 26,635 | 197.84% | 58,142 | Jun 30, 2024 |
As of Jun 30 2024, Lyell Immunopharma's largest institutional buyer is ORBIMED ADVISORS LLC. The company purchased 6.21M stocks of LYEL, valued at $9.29M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 0.66% | 0.55% | 1,670,000 | -1,685,000 | -50.22% | 2,421,500 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.32% | 0.00% | 809,560 | -1,227,112 | -60.25% | 1,173,862 | Jun 30, 2024 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.23% | 0.00% | 577,319 | -963,521 | -62.53% | 837,113 | Jun 30, 2024 |
| INVENOMIC CAPITAL MANAGEMENT LP | - | - | - | -871,525 | -100.00% | - | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.04% | - | 97,143 | -557,479 | -85.16% | 140,857 | Jun 30, 2024 |
| WUXI APPTEC CO., LTD. | 3.02% | 47.74% | 7,682,156 | -498,522 | -6.09% | 11,139,126 | Jun 30, 2024 |
| BLACKROCK INC. | 5.31% | 0.00% | 13,495,132 | -397,495 | -2.86% | 19,567,942 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.06% | 0.00% | 152,300 | -271,200 | -64.04% | 220,835 | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -245,083 | -100.00% | - | Jun 30, 2024 |
| NEW YORK LIFE INVESTMENT MANAGEMENT LLC | - | - | - | -183,805 | -100.00% | - | Jun 30, 2024 |
| CAXTON ASSOCIATES LP | - | - | - | -174,657 | -100.00% | - | Jun 30, 2024 |
| BAILLIE GIFFORD & CO | 0.20% | 0.00% | 519,998 | -136,159 | -20.75% | 753,998 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | - | - | - | -130,000 | -100.00% | - | Jun 30, 2024 |
| LIGHTHOUSE INVESTMENT PARTNERS, LLC | - | - | - | -123,002 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | 0.03% | - | 84,813 | -114,365 | -57.42% | 122,979 | Jun 30, 2024 |
| MORGAN STANLEY | 0.18% | 0.00% | 450,760 | -94,607 | -17.35% | 653,603 | Jun 30, 2024 |
| BARCLAYS PLC | 0.02% | - | 58,300 | -88,241 | -60.22% | 84,000 | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -85,524 | -100.00% | - | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -77,952 | -100.00% | - | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.14% | 0.00% | 349,017 | -76,658 | -18.01% | 506,075 | Jun 30, 2024 |
As of Jun 30 2024, Lyell Immunopharma's biggest institutional seller is OPALEYE MANAGEMENT INC.. The company sold -1.69M shares of LYEL, valued at $2.42M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IKARIAN CAPITAL, LLC | 0.21% | 0.13% | 526,066 | 526,066 | 100.00% | 762,796 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.14% | 0.00% | 367,677 | 367,677 | 100.00% | 533,132 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.12% | 0.00% | 312,406 | 312,406 | 100.00% | 452,989 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.06% | 0.00% | 139,880 | 139,880 | 100.00% | 202,826 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.03% | 0.00% | 86,454 | 86,454 | 100.00% | 125,358 | Jun 30, 2024 |
| JONES FINANCIAL COMPANIES LLLP | 0.01% | - | 26,000 | 26,000 | 100.00% | 37,700 | Jun 30, 2024 |
| OMERS ADMINISTRATION CORP | 0.01% | 0.00% | 14,200 | 14,200 | 100.00% | 20,590 | Jun 30, 2024 |
| ALGERT GLOBAL LLC | 0.01% | 0.00% | 12,759 | 12,759 | 100.00% | 19,000 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | 0.00% | - | 3,362 | 3,362 | 100.00% | 4,000 | Jun 30, 2024 |
| TYLER-STONE WEALTH MANAGEMENT | 0.00% | 0.00% | 850 | 850 | 100.00% | 1,233 | Jun 30, 2024 |
| MACQUARIE GROUP LTD | 0.00% | - | 505 | 505 | 100.00% | 732 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | - | - | 100 | 100 | 100.00% | 145,000 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | - | - | 95 | 95 | 100.00% | 138 | Jun 30, 2024 |
| ROTHSCHILD INVESTMENT LLC | - | - | 50 | 50 | 100.00% | 73 | Jun 30, 2024 |
Lyell Immunopharma's largest new institutional shareholder by number of shares is IKARIAN CAPITAL, LLC, purchased 526.07K shares, valued at $762.80K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| INVENOMIC CAPITAL MANAGEMENT LP | - | - | - | -871,525 | -100.00% | - | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -245,083 | -100.00% | - | Jun 30, 2024 |
| NEW YORK LIFE INVESTMENT MANAGEMENT LLC | - | - | - | -183,805 | -100.00% | - | Jun 30, 2024 |
| CAXTON ASSOCIATES LP | - | - | - | -174,657 | -100.00% | - | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | - | - | - | -130,000 | -100.00% | - | Jun 30, 2024 |
| LIGHTHOUSE INVESTMENT PARTNERS, LLC | - | - | - | -123,002 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -85,524 | -100.00% | - | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | - | - | - | -77,952 | -100.00% | - | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -73,704 | -100.00% | - | Jun 30, 2024 |
| AQR CAPITAL MANAGEMENT LLC | - | - | - | -44,244 | -100.00% | - | Jun 30, 2024 |
| STATE OF WYOMING | - | - | - | -42,858 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -38,128 | -100.00% | - | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -28,756 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -26,727 | -100.00% | - | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | - | - | - | -25,304 | -100.00% | - | Jun 30, 2024 |
| GRAHAM CAPITAL MANAGEMENT, L.P. | - | - | - | -21,776 | -100.00% | - | Jun 30, 2024 |
| ZACKS INVESTMENT MANAGEMENT | - | - | - | -14,127 | -100.00% | - | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -7,921 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -6,800 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -6,619 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -34 | -100.00% | - | Jun 30, 2024 |
Lyell Immunopharma's largest sold out institutional shareholder by shares sold is INVENOMIC CAPITAL MANAGEMENT LP, sold -0.87M shares, valued at -, as of undefined.
Lyell Immunopharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 1.52% | 5,055,734 | 9,956 | 0.20% | Mar 31, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.30% | 1,486,286 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.20% | 105,726 | - | - | Mar 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.15% | 241,700 | 15,345 | 6.78% | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED ALPHADEX FUND | 0.08% | 303,299 | - | - | Jan 31, 2024 |
| NORTHERN LIGHTS FUND TRUST II | 0.08% | 886,731 | 886,731 | - | Jan 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.06% | 200,096 | 3,255 | 1.65% | Feb 29, 2024 |
| IndexIQ ETF Trust | 0.06% | 137,851 | -9,645 | -6.54% | Jan 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.05% | 1,539,568 | -79,007 | -4.88% | Feb 29, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.05% | 310,130 | - | - | Mar 31, 2024 |
| Vericimetry Funds | 0.05% | 4,460 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.05% | 27,354 | - | - | Mar 31, 2024 |
| MFS SERIES TRUST I | 0.03% | 676,627 | - | - | Feb 29, 2024 |
| ETFis Series Trust I | 0.03% | 40,625 | 11,964 | 41.74% | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.03% | 11,725,217 | -2,605,673 | -18.18% | Mar 31, 2024 |
| Federated Hermes Equity Funds | 0.02% | 447,332 | - | - | Jan 31, 2024 |
| Nushares ETF Trust | 0.02% | 155,970 | 11,037 | 7.62% | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.02% | 4,069 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.01% | 462,701 | - | - | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.01% | 1,543,629 | 14,621 | 0.96% | Feb 29, 2024 |
| MFS VARIABLE INSURANCE TRUST | 0.01% | 211,803 | 1,186 | 0.56% | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.01% | 17,114 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 362,253 | - | - | Feb 29, 2024 |
| MFS VARIABLE INSURANCE TRUST III | 0.01% | 87,557 | 24,322 | 38.46% | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 97,604 | 15,643 | 19.09% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 124,919 | -8,533 | -6.39% | Mar 31, 2024 |
| VICTORY PORTFOLIOS | 0.00% | 124,720 | - | - | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 64,010 | -1,020 | -1.57% | Jan 31, 2024 |
| MORGAN STANLEY INSTITUTIONAL FUND INC | 0.00% | 237,951 | - | - | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 37,936 | -3,119 | -7.60% | Mar 31, 2024 |
| FEDERATED HERMES INSURANCE SERIES | 0.00% | 13,200 | - | - | Mar 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 239,313 | 234 | 0.10% | Jan 31, 2024 |
| BAILLIE GIFFORD FUNDS | 0.00% | 24,037 | - | - | Mar 28, 2024 |
| Direxion Shares ETF Trust | 0.00% | 333,680 | - | - | Jan 31, 2024 |
| Managed Portfolio Series | 0.00% | 47,763 | - | - | Mar 31, 2024 |
| TARGET PORTFOLIO TRUST | 0.00% | 39,600 | - | - | Jan 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 58,585 | -14,623 | -19.97% | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 8,855 | - | - | Mar 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 425,686 | 2,178 | 0.51% | Feb 29, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 4,483 | - | - | Mar 31, 2024 |
| Federated Hermes Global Allocation Fund | 0.00% | 15,707 | 2,920 | 22.84% | Feb 29, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 828,046 | 29,228 | 3.66% | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 158,578 | 29,998 | 23.33% | Feb 29, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 60,300 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 9,214 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 71,141 | -1,437 | -1.98% | Mar 28, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 11,054 | 1,544 | 16.24% | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 574,711 | -24,720 | -4.12% | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 7,499,409 | -410,448 | -5.19% | Mar 31, 2024 |
| BLACKROCK LARGE CAP SERIES FUNDS, INC. | 0.00% | 19,649 | -2,183 | -10.00% | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 760,925 | 81,004 | 11.91% | Feb 29, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 1,583 | - | - | Dec 31, 2023 |
| FLEXSHARES TRUST | 0.00% | 28,220 | - | - | Jan 31, 2024 |
| LoCorr Investment Trust | 0.00% | 7,600 | - | - | Mar 31, 2024 |
| JPMORGAN TRUST II | 0.00% | 250,116 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 30,767 | -98 | -0.32% | Jan 31, 2024 |
| VALIC Co I | 0.00% | 66,598 | -269 | -0.40% | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 28,216 | -592 | -2.05% | Mar 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 6,000 | - | - | Mar 28, 2024 |
| J.P. Morgan Exchange-Traded Fund Trust | 0.00% | 87,860 | - | - | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 601,590 | 102,685 | 20.58% | Jan 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 785 | - | - | Dec 31, 2023 |
| ALLSPRING MASTER TRUST | 0.00% | 12,393 | - | - | Feb 29, 2024 |
| Two Roads Shared Trust | 0.00% | 7,148 | 2,254 | 46.06% | Jan 31, 2024 |
| PROSHARES TRUST | 0.00% | 44,246 | 5,857 | 15.26% | Feb 29, 2024 |
| Virtus Event Opportunities Trust | 0.00% | 400 | - | - | Mar 28, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 136,671 | 58,855 | 75.63% | Mar 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 756 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 1,347 | -114 | -7.80% | Mar 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 9,434 | - | - | Mar 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 30,800 | - | - | Jan 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 227,115 | - | - | Mar 31, 2024 |
| SPDR SERIES TRUST | 0.00% | 3,411,027 | - | - | Mar 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 104 | - | - | Dec 31, 2023 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 166,695 | 5,279 | 3.27% | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 7,232 | - | - | Feb 29, 2024 |
| HC CAPITAL TRUST | 0.00% | 2,289 | - | - | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 16,496 | 3,254 | 24.57% | Jan 31, 2024 |
| MFS SERIES TRUST XV | 0.00% | 1,447 | -34 | -2.30% | Jan 31, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 20,686 | - | - | Feb 29, 2024 |
| Brighthouse Funds Trust II | 0.00% | 58,407 | -1,007 | -1.69% | Mar 31, 2024 |
| Pacer Funds Trust | 0.00% | 2,445 | - | - | Jan 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 19,661 | -79 | -0.40% | Jan 31, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 3,150 | - | - | Feb 29, 2024 |
| COLUMBIA FUNDS SERIES TRUST I | 0.00% | 225,549 | 175,907 | 354.35% | Feb 29, 2024 |
| PACIFIC SELECT FUND | 0.00% | 152,434 | -8,040 | -5.01% | Mar 31, 2024 |
| PACIFIC FUNDS SERIES TRUST | 0.00% | 10,603 | 4,041 | 61.58% | Mar 31, 2023 |
| FIDELITY SALEM STREET TRUST | 0.00% | 128,528 | -4,878 | -3.66% | Mar 31, 2024 |
| Dimensional ETF Trust | 0.00% | 10,833 | - | - | Jan 31, 2024 |
| MFS SERIES TRUST X | 0.00% | 236,865 | -7,462 | -3.05% | Feb 29, 2024 |
| ADVANCED SERIES TRUST | 0.00% | 77,383 | - | - | Mar 28, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 6,709 | 2,298 | 52.10% | Feb 29, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 18,449 | - | - | Jan 31, 2024 |
| Bridge Builder Trust | 0.00% | 73,626 | - | - | Mar 31, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 1,702 | - | - | Mar 31, 2024 |
| MERGER FUND | 0.00% | 100 | - | - | Mar 28, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 3,100 | - | - | Jan 31, 2024 |
| John Hancock Funds II | 0.00% | 136,465 | 39,155 | 40.24% | Feb 29, 2024 |
| Brighthouse Funds Trust I | 0.00% | 68,667 | - | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 7,678 | - | - | Dec 31, 2023 |
Lyell Immunopharma's largest mutual fund holder by % of total assets is "T. Rowe Price Health Sciences Fund, Inc.", owning 5.06M shares, compromising 1.52% of its total assets.
Lyell Immunopharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 116 | -5.69% |
| 31 Mar, 24 | 123 | 5.13% |
| 31 Dec, 23 | 117 | 12.50% |
| 30 Sep, 23 | 104 | 5.05% |
| 30 Jun, 23 | 99 | 1.02% |
| 31 Mar, 23 | 98 | 4.26% |
| 31 Dec, 22 | 94 | 9.30% |
| 30 Sep, 22 | 86 | 19.44% |
| 30 Jun, 22 | 72 | -8.86% |
| 31 Mar, 22 | 79 | 2.60% |
| 31 Dec, 21 | 77 | 24.19% |
| 30 Sep, 21 | 62 | 19.23% |
| 30 Jun, 21 | 52 | - |
As of 30 Jun 24, 116 institutions are holding Lyell Immunopharma's shares, representing a decrease of -5.69% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 133,324,052 | 0.44% |
| 31 Mar, 24 | 132,733,881 | 1.13% |
| 31 Dec, 23 | 131,255,797 | 7.18% |
| 30 Sep, 23 | 122,457,371 | 0.23% |
| 30 Jun, 23 | 122,180,099 | 3.79% |
| 31 Mar, 23 | 117,716,756 | 0.95% |
| 31 Dec, 22 | 116,611,726 | 3.85% |
| 30 Sep, 22 | 112,285,479 | 6.37% |
| 30 Jun, 22 | 105,561,521 | 6.13% |
| 31 Mar, 22 | 99,468,037 | 16.28% |
| 31 Dec, 21 | 85,541,129 | 3.64% |
| 30 Sep, 21 | 82,534,486 | 3.55% |
| 30 Jun, 21 | 79,701,894 | - |
Lyell Immunopharma (LYEL) has 133.32M shares outstanding as of 30 Jun 24, up 0.44% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 52.44% | 1.91% |
| 31 Mar, 24 | 52.45% | 1.92% |
| 31 Dec, 23 | 52.23% | 2.18% |
| 30 Sep, 23 | 48.94% | 2.04% |
| 30 Jun, 23 | 48.95% | 2.20% |
| 31 Mar, 23 | 47.16% | 2.12% |
| 31 Dec, 22 | 47.20% | 2.31% |
| 30 Sep, 22 | 45.22% | 2.46% |
| 30 Jun, 22 | 42.86% | 2.58% |
| 31 Mar, 22 | 40.74% | 1.03% |
| 31 Dec, 21 | 62.94% | 1.71% |
| 30 Sep, 21 | 60.72% | 1.77% |
| 30 Jun, 21 | 58.64% | - |
As of 30 Jun 24, Lyell Immunopharma is held by 52.44% institutional shareholders, representing a 1.91% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 49 | -14.04% |
| 31 Mar, 24 | 57 | -1.72% |
| 31 Dec, 23 | 58 | -4.92% |
| 30 Sep, 23 | 61 | 32.61% |
| 30 Jun, 23 | 46 | -6.12% |
| 31 Mar, 23 | 49 | - |
| 31 Dec, 22 | 49 | -10.91% |
| 30 Sep, 22 | 55 | 48.65% |
| 30 Jun, 22 | 37 | -28.85% |
| 31 Mar, 22 | 52 | - |
| 31 Dec, 21 | 52 | 33.33% |
| 30 Sep, 21 | 39 | -25.00% |
| 30 Jun, 21 | 52 | - |
49 institutional shareholders have increased their position in LYEL stock as of 30 Jun 24 compared to 57 in the previous quarter (a -14.04% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 43 | -2.27% |
| 31 Mar, 24 | 44 | 46.67% |
| 31 Dec, 23 | 30 | 42.86% |
| 30 Sep, 23 | 21 | -38.24% |
| 30 Jun, 23 | 34 | 41.67% |
| 31 Mar, 23 | 24 | 33.33% |
| 31 Dec, 22 | 18 | 38.46% |
| 30 Sep, 22 | 13 | -31.58% |
| 30 Jun, 22 | 19 | 90.00% |
| 31 Mar, 22 | 10 | -9.09% |
| 31 Dec, 21 | 11 | - |
| 30 Sep, 21 | 11 | - |
| 30 Jun, 21 | - | - |
43 institutional shareholders have reduced their position in LYEL stock as of 30 Jun 24 compared to 44 in the previous quarter (a -2.27% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 116 | -5.69% | 133,324,052 | 0.44% | 52.44% | 1.91% | 49 | -14.04% | 43 | -2.27% |
| 31 Mar, 24 | 123 | 5.13% | 132,733,881 | 1.13% | 52.45% | 1.92% | 57 | -1.72% | 44 | 46.67% |
| 31 Dec, 23 | 117 | 12.50% | 131,255,797 | 7.18% | 52.23% | 2.18% | 58 | -4.92% | 30 | 42.86% |
| 30 Sep, 23 | 104 | 5.05% | 122,457,371 | 0.23% | 48.94% | 2.04% | 61 | 32.61% | 21 | -38.24% |
| 30 Jun, 23 | 99 | 1.02% | 122,180,099 | 3.79% | 48.95% | 2.20% | 46 | -6.12% | 34 | 41.67% |
| 31 Mar, 23 | 98 | 4.26% | 117,716,756 | 0.95% | 47.16% | 2.12% | 49 | - | 24 | 33.33% |
| 31 Dec, 22 | 94 | 9.30% | 116,611,726 | 3.85% | 47.20% | 2.31% | 49 | -10.91% | 18 | 38.46% |
| 30 Sep, 22 | 86 | 19.44% | 112,285,479 | 6.37% | 45.22% | 2.46% | 55 | 48.65% | 13 | -31.58% |
| 30 Jun, 22 | 72 | -8.86% | 105,561,521 | 6.13% | 42.86% | 2.58% | 37 | -28.85% | 19 | 90.00% |
| 31 Mar, 22 | 79 | 2.60% | 99,468,037 | 16.28% | 40.74% | 1.03% | 52 | - | 10 | -9.09% |
| 31 Dec, 21 | 77 | 24.19% | 85,541,129 | 3.64% | 62.94% | 1.71% | 52 | 33.33% | 11 | - |
| 30 Sep, 21 | 62 | 19.23% | 82,534,486 | 3.55% | 60.72% | 1.77% | 39 | -25.00% | 11 | - |
| 30 Jun, 21 | 52 | - | 79,701,894 | - | 58.64% | - | 52 | - | - | - |
Lyell Immunopharma Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
All Insider Owners Trades
Lyell Immunopharma Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2023 | 8 | 1 | 800.00% |
| Q2 2023 | 7 | - | - |
| Q1 2023 | 5 | - | - |
| Q4 2022 | 2 | - | - |
| Q3 2022 | 1 | - | - |
| Q2 2022 | 8 | - | - |
| Q1 2022 | 6 | 2 | 300.00% |
| Q4 2021 | 1 | 1 | 100.00% |
| Q3 2021 | 1 | - | - |
| Q2 2021 | 7 | 30 | 23.33% |
8 total buy trades, and 1 total sell trades (buy/sell ratio of 8.00%) were made by Lyell Immunopharma's insiders, as of Q3 2023.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2023 | - | 1 | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q3 2021 | - | - | - |
| Q2 2021 | 1 | - | - |
As of Q3 2023, Insider owners conducted 0 open market buy trades and 1 open market sell trades of Lyell Immunopharma's stocks.
Lyell Immunopharma Peer Ownership
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| NUVB | Nuvation Bio Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| MRUS | Merus N.V. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| INBX | Inhibrx, Inc. |
| GBIO | Generation Bio Co. |
| KRON | Kronos Bio, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| STTK | Shattuck Labs, Inc. |
LYEL Ownership FAQ
Who Owns Lyell Immunopharma?
Lyell Immunopharma is owned by institutional shareholders (52.44%), insiders (15.34%), and public (32.23%). The largest institutional shareholder of Lyell Immunopharma is MWG MANAGEMENT LTD. (7.93% of total shares) and the top mutual fund owner is T. Rowe Price Health Sciences Fund, Inc. (1.52% of total shares).
Who are the major institutional shareholders of Lyell Immunopharma?
Lyell Immunopharma's major institutional shareholders are MWG MANAGEMENT LTD., ORLAND PROPERTIES LTD, BLACKROCK INC., VANGUARD GROUP INC, and FORESITE CAPITAL MANAGEMENT IV, LLC. The top five shareholders own together 27.72% of the company's share outstanding.
How many Lyell Immunopharma shareholders are there?
As of Jun 2024, there are 116 institutional shareholders of Lyell Immunopharma.
What percentage of Lyell Immunopharma is owned by MWG MANAGEMENT LTD?
MWG MANAGEMENT LTD owns 20.16M shares of Lyell Immunopharma, representing 7.93% of the company's total shares outstanding, valued at $29.24M (as of Jun 2024).
What percentage of Lyell Immunopharma is owned by ORLAND PROPERTIES LTD?
As of Jun 2024, ORLAND PROPERTIES LTD holds 15.09M shares of Lyell Immunopharma (LYEL), compromising 5.94% of the company, valued at $21.89M.
What percentage of Lyell Immunopharma is owned by BLACKROCK INC?
BLACKROCK INC is the third largest holder of Lyell Immunopharma. The company owns 13.5M of the company's shares outstanding (worth $19.57M).